window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 21, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

neurodegenerative disease research

  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Genomics and sequencing,Therapeutic Areas

    Meteor Biotech joins South Korea consortium to advance brain organoid commercialisation platform

    Meteor Biotech has joined a South Korean government-backed consortium aimed [...]

    June 23, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    PRISM ALS initiative develops patient-derived stem cell models to improve ALS/MND drug discovery

    A new global initiative aims to address long-standing limitations in [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Therapeutic Areas

    Rainwater Charitable Foundation announces 2026 Rainwater Prize winners for tauopathy research

    The Rainwater Charitable Foundation (RCF) has announced the recipients of [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Adneuris licenses Phase 3 pain therapy cebranopadol to Conba for Greater China
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics
  • Latent Labs opens lab-validated AI drug design platform to researchers worldwide
    Categories: Digital & Data, Drug Discovery & Development, Research & Development
  • PET imaging reveals widespread synaptic loss in schizophrenia
    Categories: Clinical & Regulatory, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top